Please login to the form below

Not currently logged in
Email:
Password:

Watson completes Actavis acquisition, will rebrand in 2013

Will bring its global operations under the Actavis name from next year

Watson Pharmaceuticals 

Watson Pharmaceuticals has finalised its €4.3bn acquisition of Icelandic generics company Actavis and is planning a major rebrand of its global operations.

The deal will make the combined firm the third-largest generics company, after Teva and Novartis' Sandoz unit, with a presence in more than 60 markets and anticipated pro-forma 2012 revenues of over $8bn.

From 2013 the US firm Watson Pharmaceuticals will begin rebranding its global operations, adopting the Actavis name in order to present a unified brand to the market.

“When we announced the proposed acquisition of Actavis in April 2012, we immediately instituted an extensive and accelerated review of our global brand position and naming equities,” said Paul Bisaro, president and CEO of Watson. 

Bisaro explained that after Watson launched in 1984, the corporate name was not registered globally and later, during the global expansion strategy, which was initiated in 2009, the company felt they could not generate a unified market presence under the Watson brand. 

"With our expansion into more than 60 commercial markets around the world, we recognised the many benefits of uniting our company under one name to all stakeholders – customers, consumers, payers, institutions and shareholders and potential shareholders. 

The process saw Watson consider more than 2,000 potential new names, Bisaro said, before concluding that one of the assets his company gained from acquiring Actavis was a single name, trademarked and protected around the world.

Watson expect to be able to make annual cost savings in purchasing and raw materials of some $300m from the €4.3bn acquisition within three years and said the deal “substantially completes Watson's expansion as a leading global generics company”.

The firm will officially rollout its new identity in 2013, with a campaign that will involve facilities, operations and its commercial presences.

8th November 2012

From: Sales, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics